LifeTech Scientific (HKG:1302) expects attributable profit for the first half of 2026 to fall to about 110 million yuan to 120 million yuan, from 238.5 million yuan a year earlier, according to a Wednesday Hong Kong bourse filing.
The medical device company attributed the expected decline mainly to lower revenue and a significant decrease in net exchange gains.
The company expects to publish its interim results by the end of August.
Shares of LifeTech were down more than 3% in Thursday morning trade.